Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy)

Table 1

Characteristics of ONJ patients.

	𝑁	%
Total	200
Age	Mean 68 years; (SD: 9.23 years)
Gender
Female	121	60.5
Male	79	39.5
Bone disease
Metastatic breast cancer	78	39.0
Myeloma	64	32.0
Metastatic prostate cancer	32	16.0
Bone metastases of other types of cancer*	16*	8.0
Osteoporosis in cancer patients	10	5.0
Bisphosphonates
Zoledronate iv only	127	63.5
Pamidronate iv only	16	8.0
Pamidronate iv/zoledronate iv	43	21.5
Alendronate os	3	1.5
Clodronate im	1	0.5
Zoledronate iv/pamidronate iv	5	2.5
Zoledronate iv/ibandronate iv	3	1.5
Zoledronate iv/ibandronate os	1	0.5
Alendronate os/pamidronate; iv/zoledronate iv	1	0.5

∗Lung n.9; kidney n.3; bladder n.2; rectum n.1; occult primary n.1.